Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.

[1]  D. Linehan,et al.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.

[2]  A. Adjei,et al.  Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. , 2015, The oncologist.

[3]  Michael Biehl,et al.  Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of rheumatoid arthritis , 2015, Annals of the rheumatic diseases.

[4]  F. Geissmann,et al.  Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors , 2014, Nature.

[5]  R. Jain.  Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. , 2014, Cancer cell.

[6]  Hui Li,et al.  Noncanonical NF-κB Activation Mediates STAT3-Stimulated IDO Upregulation in Myeloid-Derived Suppressor Cells in Breast Cancer , 2014, The Journal of Immunology.

[7]  R. Hynes,et al.  Platelets guide the formation of early metastatic niches , 2014, Proceedings of the National Academy of Sciences.

[8]  A. Arbab,et al.  Myeloid Derived Suppressor Cells: Fuel the Fire , 2014, Biochemistry & physiology.

[9]  B. Seliger,et al.  Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity , 2014, Clinical Cancer Research.

[10]  F. Ghiringhelli,et al.  [Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets]. , 2014, Bulletin du cancer.

[11]  Amber J. Giles,et al.  Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy , 2014, Science Translational Medicine.

[12]  D. Alizadeh,et al.  Chemotherapeutic targeting of cancer-induced immunosuppressive cells. , 2014, Cancer research.

[13]  B. Rini,et al.  Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. , 2014, Seminars in oncology.

[14]  J. Huse,et al.  Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier. , 2014, Cancer research.

[15]  J. Scoazec,et al.  The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. , 2014, Cancer research.

[16]  Xiao-li Zhang,et al.  Defective TGF-β signaling in bone marrow-derived cells prevents hedgehog-induced skin tumors. , 2014, Cancer research.

[17]  K. Aldape,et al.  Using the molecular classification of glioblastoma to inform personalized treatment , 2014, The Journal of pathology.

[18]  R. Sidman,et al.  CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis , 2013, Proceedings of the National Academy of Sciences.

[19]  Stephen L. Brown,et al.  Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study. , 2013, Translational oncology.

[20]  B. R. Achyut.  Impact of Microenvironment in Therapy-Induced Neovascularization ofGlioblastoma , 2013 .

[21]  S. Dey,et al.  CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. , 2013, Cancer cell.

[22]  C. Garlanda,et al.  Tumor associated macrophages and neutrophils in cancer. , 2013, Immunobiology.

[23]  M. Willis,et al.  Targeting angiogenesis and the tumor microenvironment. , 2013, Surgical oncology clinics of North America.

[24]  R. Nurieva,et al.  Generation of a novel therapeutic peptide that depletes MDSC in tumor-bearing mice , 2013, Nature Medicine.

[25]  Christina S. Leslie,et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.

[26]  Sarah E. Seton-Rogers.  Tumour microenvironment: Means of resistance , 2013, Nature Reviews Cancer.

[27]  A. Arbab,et al.  Neovascularization in Glioblastoma: Current Pitfall in Anti-angiogenic therapy. , 2013, Zhong liu za zhi.

[28]  Zhaoshi Jiang,et al.  An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy , 2013, Nature Medicine.

[29]  Jennie W. Taylor,et al.  Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. , 2013, Neuro-oncology.

[30]  J. Markowitz,et al.  Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer , 2013, Journal of Immunotherapy for Cancer.

[31]  Stephen Mok,et al.  CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. , 2013, Cancer research.

[32]  M. Trincavelli,et al.  Abstract LB-346: The Oxysterol-CXCR2 axis plays a key role in the recruitment of tumor promoting neutrophils. , 2013 .

[33]  F. Peale,et al.  Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF–induced neutrophil recruitment , 2013, Proceedings of the National Academy of Sciences.

[34]  C. Scarlett.  Contribution of bone marrow derived cells to the pancreatic tumor microenvironment , 2013, Front. Physiol..

[35]  J. Heymach,et al.  Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. , 2012, Neuro-oncology.

[36]  K. Connelly,et al.  eNOS deficiency predisposes podocytes to injury in diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[37]  J. Hamilton,et al.  CSF-1 receptor signalling from endosomes mediates the sustained activation of Erk1/2 and Akt in macrophages. , 2012, Cellular signalling.

[38]  W. Stetler-Stevenson,et al.  TIMP-2 Targets Tumor-associated Myeloid Suppressor Cells With Effects in Cancer Immune Dysfunction and Angiogenesis , 2012, Journal of immunotherapy.

[39]  H. Pan,et al.  Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. , 2012, Cancer research.

[40]  A. Arbab.  Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. , 2012, Histology and histopathology.

[41]  D. Hume,et al.  Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. , 2012, Blood.

[42]  G. Lesinski,et al.  Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. , 2011, Cancer research.

[43]  K. Alitalo,et al.  VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. , 2011, Trends in molecular medicine.

[44]  G. Dontu,et al.  Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. , 2011, Cancer research.

[45]  E. Seifried,et al.  Bone marrow derived cells in the tumour microenvironment contain cells with primitive haematopoietic phenotype , 2010, Journal of cellular and molecular medicine.

[46]  C. Patlak,et al.  The MRI‐measured arterial input function resulting from a bolus injection of Gd‐DTPA in a rat model of stroke slightly underestimates that of Gd‐[14C]DTPA and marginally overestimates the blood‐to‐brain influx rate constant determined by Patlak plots , 2010, Magnetic resonance in medicine.

[47]  Ruman Rahman,et al.  Antiangiogenic Therapy and Mechanisms of Tumor Resistance in Malignant Glioma , 2010, Journal of oncology.

[48]  A. Lusis,et al.  Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. , 2010, Blood.

[49]  Y. Meng,et al.  G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models , 2009, Proceedings of the National Academy of Sciences.

[50]  G. Ahn,et al.  Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature , 2009, Angiogenesis.

[51]  P. Wen,et al.  Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. , 2008, Current opinion in neurology.

[52]  D. Hanahan,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[53]  N. Ferrara,et al.  Role of myeloid cells in tumor angiogenesis and growth. , 2008, Trends in cell biology.

[54]  J. Hamilton.  Colony-stimulating factors in inflammation and autoimmunity , 2008, Nature Reviews Immunology.

[55]  J. Talmadge,et al.  Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. , 2008, Blood.

[56]  R. Béliveau,et al.  Tumor Environment Dictates Medulloblastoma Cancer Stem Cell Expression and Invasive Phenotype , 2008, Molecular Cancer Research.

[57]  S. Rafii,et al.  A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. , 2008, Cancer cell.

[58]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[59]  G. Ahn,et al.  Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. , 2008, Cancer cell.

[60]  P. De Baetselier,et al.  Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. , 2008, Blood.

[61]  R. Knight,et al.  Identification of Variations in Blood-Brain Barrier Opening After Cerebral Ischemia by Dual Contrast-Enhanced Magnetic Resonance Imaging and T1sat Measurements , 2008, Stroke.

[62]  F. Peale,et al.  Bv8 regulates myeloid-cell-dependent tumour angiogenesis , 2007, Nature.

[63]  D. Scadden,et al.  Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. , 2006, Cancer research.

[64]  A. Takaoka,et al.  Comparing antibody and small-molecule therapies for cancer , 2006, Nature Reviews Cancer.

[65]  David J. Yang,et al.  The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. , 2006, Neuro-oncology.

[66]  Alberto Mantovani,et al.  Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.

[67]  J. Parham,et al.  Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[68]  D. Hume,et al.  The Colony-Stimulating Factor 1 Receptor Is Expressed on Dendritic Cells during Differentiation and Regulates Their Expansion1 , 2005, The Journal of Immunology.

[69]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[70]  R. Weissleder,et al.  Bone marrow-derived lin(-)c-kit(+)Sca-1+ stem cells do not contribute to vasculogenesis in Lewis lung carcinoma. , 2005, Neoplasia.

[71]  M. Chopp,et al.  Analysis of Combined Treatment of Embolic Stroke in Rat with r-tPA and a GPIIb/IIIa Inhibitor , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[72]  M. Pesce,et al.  SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. , 2004, Blood.

[73]  B. Fingleton,et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.

[74]  Geoffrey C Gurtner,et al.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 , 2004, Nature Medicine.

[75]  Daniel J Brat,et al.  Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma , 2004, Laboratory Investigation.

[76]  Lian Li,et al.  Patlak plots of Gd‐DTPA MRI data yield blood–brain transfer constants concordant with those of 14C‐sucrose in areas of blood–brain opening , 2003, Magnetic resonance in medicine.

[77]  Andrew V. Nguyen,et al.  Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.

[78]  D. Noonan,et al.  Inflammatory angiogenesis and the tumor microenvironment as targets for cancer therapy and prevention. , 2014, Cancer treatment and research.

[79]  C. Chiang,et al.  Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model , 2012, Laboratory Investigation.

[80]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[81]  G. Sledge,et al.  Can tumor angiogenesis be inhibited without resistance? , 2005, EXS.